Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.76 |
| ▸ | P2RY6 | Q15077 | 14/20 | 0.72 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18785149 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL12595472 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL308618 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18785150 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL154172 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL29360821 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18785151 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL39904 | 1.00 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL10585778 | 0.99 | P2RY2 (0.75) | P2RY2P2RY6P2RY4 | |
| SCHEMBL22635992 | 0.99 | P2RY2 (0.75) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | disclosed |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| US-11052090-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11045474-B2 | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections | EMORY UNIVERSITY (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3750544-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF VIRAL INFECTION | Emory University (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200352948-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2020-11-12 | — | — | US | disclosed |
| US-10821111-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200316073-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2020-10-08 | — | — | US | disclosed |
| EP-1104436-A2 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B VIRUS | Idenix (Cayman) Limited (KY) | 2001-06-06 | — | — | EP | disclosed |
| US-6197777-B1 | A 1,3-OXASELENOLANE NUCLEOSIDE; VIRICIDE | EMORY UNIVERSITY | 2001-03-06 | — | — | US | disclosed |
| US-6071922-A | PYRIMIDINE-BASE NUCLEOSIDES; VIRICIDES; HIV; HEPATITIS B VIRUS; AIDS-RELATED COMPLEX; IMMUNODEFICIENCY VIRUS IN ANIMALS AND HUMANS; ANTIPROLIFERATIVE AGENTS | EMORY UNIVERSITY (US) | 2000-06-06 | — | — | US | disclosed |
| WO-2000025799-A1 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000009531-A2 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-02-24 | — | — | WO | disclosed |
| EP-0970078-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998041522-A9 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | — | 1999-03-04 | — | — | WO | disclosed |
| WO-1998041522-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 1998-09-24 | — | — | WO | disclosed |
| EP-0831852-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040164-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821111-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | P2RY2 880/4885P2RY6 689/4885P2RY4 1119/4885 |
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NUDT1, ITPA, MTAP | P2RY2 141/4885P2RY6 107/4885P2RY4 73/4885 |
| US-20200352948-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | P2RY2 555/4885P2RY6 432/4885P2RY4 538/4885 |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | P2RY2 776/4885P2RY6 736/4885P2RY4 1060/4885 |
| US-20200316073-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | P2RY2 143/4885P2RY6 104/4885P2RY4 191/4885 |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | MERTK, PNP, HAVCR2 | P2RY2 143/4885P2RY6 104/4885P2RY4 191/4885 |
| US-11045474-B2 | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections | JAK1, PNP, JAK3 | P2RY2 1090/4885P2RY6 695/4885P2RY4 1281/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | P2RY2 880/4885P2RY6 689/4885P2RY4 1119/4885 |
| US-11052090-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | MERTK, PNP, HAVCR2 | P2RY2 143/4885P2RY6 104/4885P2RY4 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.